SCHEMBL24944496

SCHEMBL24944496

CNc1nc(Nc2ccc(CN3CC4(COC4)C3)cc2Cl)c(C(N)=O)nc1-c1cncc2c1ncn2C

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LRRK2 Q5S007 9/20 0.36
▸ EGFR P00533 2/20 0.32
▸ ALK Q9UM73 2/20 0.32
▸ PDCD1 Q15116 1/20 0.32
▸ CD274 Q9NZQ7 1/20 0.32
▸ TLR8 Q9NR97 1/20 0.31
▸ TLR7 Q9NYK1 1/20 0.31
▸ CCNC P24863 2/20 0.31
▸ CDK8 P49336 2/20 0.31
▸ YTHDC1 Q96MU7 1/20 0.31
▸ TTK P33981 1/20 0.31
▸ INSR P06213 1/20 0.30
▸ SMC2 O95347 1/20 0.30
▸ CSNK2A2 P19784 1/20 0.30
▸ MAP2K2 P36507 1/20 0.30
▸ MAP2K1 Q02750 1/20 0.30
▸ SMC1A Q14683 1/20 0.30
▸ AAK1 Q2M2I8 1/20 0.30
▸ Q6ZSR9 Q6ZSR9 1/20 0.30
▸ BMP2K Q9NSY1 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Formic Acid SCHEMBL30205591 0.97 LRRK2 (0.35) LRRK2EGFRALKPDCD1CD274
SCHEMBL30206337 0.93 LRRK2 (0.39) LRRK2EGFRALKPDCD1CD274
SCHEMBL30801879 0.92 IKBKE (0.35) LRRK2ALKPDCD1CD274TLR8
SCHEMBL24944188 0.92 IKBKE (0.35) LRRK2ALKPDCD1CD274TLR8
SCHEMBL24944494 0.91 LRRK2 (0.42) LRRK2EGFRALKCCNCCDK8
Formic Acid SCHEMBL30206162 0.90 IKBKE (0.33) LRRK2ALKPDCD1CD274TLR8
SCHEMBL31577238 0.85 LRRK2 (0.36) LRRK2TLR8TLR7TTK
SCHEMBL30206172 0.85 LRRK2 (0.35) LRRK2EGFRPDCD1CD274TLR8
SCHEMBL24944783 0.84 LRRK2 (0.41) LRRK2EGFRALKCCNCCDK8
SCHEMBL24944183 0.83 SYK (0.44) ALKCCNCCDK8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023001794-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2023-01-26 — — WO disclosed
Send feedback